期刊文献+

理气化瘀汤治疗气滞血瘀型原发性痛经 被引量:13

Clinical Study of Liqi Huayu decoction in treating qi stagnation and blood stasis type primary dysmenorrhea
在线阅读 下载PDF
导出
摘要 目的观察理气化瘀汤对气滞血瘀型原发性痛经患者疗效的影响。方法采用随机临床对照研究方法,将148例患者分为对照组74例,治疗组74例。对照组予常规隔下逐瘀汤,治疗组予理气化瘀汤,通过比较VAS疼痛评分、COX痛经症状积分及用药安全性来评价理气化瘀汤的临床疗效。结果经过3个月经周期的治疗,治疗组(理气化瘀汤)能明显降低患者VAS疼痛评分(3.83±1.52 vs 5.37±1.73),COX痛经症状积分(0.87±0.39 vs1.32±0.47;6.43±1.56 vs 8.87±1.73),与对照组比较差异具有统计学意义(P<0.05);同时治疗组对肝功能、肾功能无明显不良影响(P>0.05)。结论理气化瘀汤能有效安全缓解气滞血瘀型原发性痛经患者临床症状,改善患者生活质量。 Objective To observe the effect of Liqi Huayu decoction in treating qi stagnation and blood stasis type primary dysmenorrhea patients. Methods Using randomized controlled clinical trial method, 148 patients were divided into control group(n = 74) and treatment group(n = 74). The control group was received Gexiao zhuyu decoction; the treatment group was received Liqi Huayu decoction, by means of the index of VAS and COX of primary dysmenorrhea patients for evaluating curative effect. Results On 3 menstrual cycle of treatment, the index of VAS(3.83±1.52 vs. 5.37±1.73) and COX(0.87±0.39 vs. 1.32±0.47;6.43±1.56 vs. 8.87±1.73) with patients can be reduced, the diff erence was statistically significant compared with the control group(P〈0.05); Meanwhile, the treatment group cannot aff ect liver function and renal function of primary dysmenorrhea patients(P〉0.05). Conclusion Liqi Huayu decoction can effectively and safely alleviate the clinical symptoms of qi stagnation and blood stasis type primary dysmenorrhea patients.
作者 孙莺 沈维增 陈云霞 陈兆鑫 张海艇 SUN Ying;SHEN Weizeng;CHEN Yunxia;CHEN Zhaoxin;ZHANG Haiting(Shenzhen People's Hospital of Baoan District Affiliated to Southem Medical University,Shenzhen 518101,Guangdong Province,China)
出处 《吉林中医药》 2018年第9期1038-1041,共4页 Jilin Journal of Chinese Medicine
基金 广东省科技计划项目(2015A030302256)
关键词 原发性痛经 理气化瘀汤 疼痛评分 痛经症状评分 primary dysmenorrhea Liqi Huayu decoction VAS the cox menstrual symptom scale
  • 相关文献

参考文献5

二级参考文献31

  • 1李迎春,郑蓓蓓.川楝子不同炮制品镇痛抗炎作用研究[J].河北北方学院学报(自然科学版),2013,29(2):73-75. 被引量:14
  • 2金小高,罗爱林,张广雄.三种大鼠神经病理性疼痛模型的制备和效果比较[J].临床麻醉学杂志,2005,21(5):338-340. 被引量:43
  • 3侴桂新,中村■夫,马超美,王峥涛,服部征雄.乌药中异喹啉类生物碱(英文)[J].中国天然药物,2005,3(5):272-275. 被引量:16
  • 4王军伟,阮冰.乌药的植化及药理研究概况[J].浙江中医杂志,2006,41(11):675-677. 被引量:55
  • 5中华人民共和国卫生部.中药新药临床研究指导原则第一辑[M].北京:人民卫生出版社,1993:1-5.
  • 6徐淑云.药理实验方法学[M].北京:人民卫生出版社,2001.856.
  • 7Anand P, Whiteside G, Fowler CJ, et al. Targeting CB2 re- ceptors and the endocannahinoid system for the treatment of pain. Brain Res Re, 2009,60(1):255-266.
  • 8Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 1988, 33(1) : 87-107.
  • 9Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and in- flammatory pain. Br J Pharmacol, 2007, 152(5) :624-632.
  • 10Hwang J, Adamson C, Butler D, et al. Enhancement of en- docannabinoid signaling by fatty acid amide hydrolase inhibi- tion: a neuroprotective therapeutic modality. Life Sci, 2010, 86(15-16) : 615-623.

共引文献162

同被引文献112

引证文献13

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部